ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus (T2DM) are highly prevalent diseases and are closely associated, with NAFLD being present in the majority of T2DM patients. In Asian traditional medicine, Mori Cortex is widely used for the treatment of diabetes and hyperlipidemia. However, whether it has a therapeutic effect on T2DM associated with NAFLD is still unknown. The present study showed that the oral treatment with Mori Cortex extract (MCE; 10 g·kg·d) lowered the blood lipid levels and reversed insulin resistance (IR) in high fat-diet/streptozotocin-induced type 2 diabetes in rats. The expression levels of sterol receptor element-binding protein-1c (SREBP-1c) and carbohydrate-responsive element binding protein (ChREBP), which are involved in steatosis in NAFLD rats, were measured in the liver samples. MCE decreased the protein and mRNA expression levels of SREBP-1c and ChREBP. In conclusion, down-regulation of SREBP-1c and ChREBP might contribute to the protective effect of MCE on hepatic injury and IR in the rats with T2DM associated with NAFLD.
Subject(s)
Animals , Male , Rats , Alanine Transaminase , Blood , Aspartate Aminotransferases , Blood , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Genetics , Diabetes Mellitus, Type 2 , Blood , Drug Therapy , Metabolism , Diet, High-Fat , Disease Models, Animal , Down-Regulation , Insulin , Blood , Insulin Resistance , Physiology , Lipid Metabolism , Genetics , Liver , Morus , Non-alcoholic Fatty Liver Disease , Blood , Drug Therapy , Metabolism , Phytotherapy , Plant Extracts , Pharmacology , Therapeutic Uses , Rats, Sprague-Dawley , StreptozocinABSTRACT
Nonalcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus (T2DM) are highly prevalent diseases and are closely associated, with NAFLD being present in the majority of T2DM patients. In Asian traditional medicine, Mori Cortex is widely used for the treatment of diabetes and hyperlipidemia. However, whether it has a therapeutic effect on T2DM associated with NAFLD is still unknown. The present study showed that the oral treatment with Mori Cortex extract (MCE; 10 g·kg·d) lowered the blood lipid levels and reversed insulin resistance (IR) in high fat-diet/streptozotocin-induced type 2 diabetes in rats. The expression levels of sterol receptor element-binding protein-1c (SREBP-1c) and carbohydrate-responsive element binding protein (ChREBP), which are involved in steatosis in NAFLD rats, were measured in the liver samples. MCE decreased the protein and mRNA expression levels of SREBP-1c and ChREBP. In conclusion, down-regulation of SREBP-1c and ChREBP might contribute to the protective effect of MCE on hepatic injury and IR in the rats with T2DM associated with NAFLD.
Subject(s)
Animals , Male , Rats , Alanine Transaminase , Blood , Aspartate Aminotransferases , Blood , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Genetics , Diabetes Mellitus, Type 2 , Blood , Drug Therapy , Metabolism , Diet, High-Fat , Disease Models, Animal , Down-Regulation , Insulin , Blood , Insulin Resistance , Physiology , Lipid Metabolism , Genetics , Liver , Morus , Non-alcoholic Fatty Liver Disease , Blood , Drug Therapy , Metabolism , Phytotherapy , Plant Extracts , Pharmacology , Therapeutic Uses , Rats, Sprague-Dawley , StreptozocinABSTRACT
<p><b>OBJECTIVE</b>To explore the effects of hepatitis B immune globulin (HBIG) in prevention of mother-to-infant hepatitis B virus (HBV) transmission.</p><p><b>METHOD</b>A total of 279 pregnant women positive for HBsAg alone or for both HBsAg and HBeAg were enrolled into this study from January 2001 to May 2005. They were respectively divided into two groups at random, namely, only HBsAg-positiveexperimental group (n = 80), only HBsAg-positive control group (n = 60), both HBsAg and HBeAg-positive experimental group (n = 79) and both HBsAg and HBeAg-positive control group (n = 60). The two experimental groups were injected with HBIG once every four weeks until labor. The two control groups received no HBIG. The infants received intramuscular HBIG 16 hours after birth and two weeks later, in addition to routine immunization with hepatitis B vaccine. The infants were followed up and HBsAg was determined.</p><p><b>RESULTS</b>The HBsAg infection rates of babies in the four groups were respectively 3%, 13%, 10%, 32%. The infection rate of the infants whose mothers were injected with HBIG was significantly lower than that of the control group.</p><p><b>CONCLUSION</b>The HBIG could effectively prevent HBV transmission from mothers to infants and reduce the HBV infection rate.</p>